Olga Shashkova

Dr. Olga Shashkova


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
ETElizaveta Tyshchuk
Elizaveta Tyshchuk
EDElizaveta Denisova
Elizaveta Denisova
PGPolina Grebenkina
Polina Grebenkina
MPMarina Pereviazkina
Marina Pereviazkina
ASAnastasia Stolbovaya
Anastasia Stolbovaya
Dmitry I SokolovDmitry I Sokolov
Dmitry I Sokolov
MICA/B molecules (MICs) are stress-induced molecules expressed by infected and tumor cells. Their expression also characterizes trophoblast cells. Cytotoxic lymphocytes, including natural killer (NK) cells, express the NKG2D receptor, aiding them in the recognition and destruction of target cells that present MICs. To evade destruction, target cells employ various defense mechanisms, including the secretion of soluble forms of MICs. Choriocarcinoma JEG-3 cells and NK-92 cells were used to assess the expression of MICs and NKG2D. The cytotoxicity of NK-92 cells against JEG-3 cells in the presence of trichostatin A (TSA), anti-MICA/B antibodies (anti-MICA/B), and recombinant MIC proteins (rMICA/B) was evaluated. JEG-3 cells and NK-92 cells express MICs. Additionally, NK-92 cells exhibit high levels of NKG2D receptor expression. TSA treatment reduced the surface expression of MICs on choriocarcinoma cells, and was also associated with the release of soluble MICB. However, the TSA-induced decrease in MIC expression by choriocarcinoma cells did not protect them from the cytotoxic effects of NK cells. Only the activation of NK cells by IL-12 resulted in a decline in susceptibility of TSA-treated choriocarcinoma cells to NK cell-mediated cytotoxicity. Thus, NK cells activated by IL-12 lose their ability to effectively kill TSA-treated choriocarcinoma cells through the MIC-mediated mechanisms.

30 October 2024 in Sovremennye tehnologii v medicine
Verified
Journal Article
Open access
OSOlga Shashkova
Olga Shashkova
LTL.A. Terekhina
L.A. Terekhina
IMI.S. Malakhov
I.S. Malakhov
APA.A. Pinevich
A.A. Pinevich
NVN.L. Vartanyan
N.L. Vartanyan
MSM.P. Samoilovich
M.P. Samoilovich
The aim of this study was to create and evaluate a cell model designed for in vitro and in vivo testing of anti-human PD-L1 therapeutic and diagnostic agents' specificity. Materials and Methods. Genetically modified cells expressing human PD-L1 (strain CT26-PD-L1) were obtained by retroviral transduction of murine CT26 carcinoma cells. PD-L1 gene activity was assessed by real-time PCR, and PD-L1 expression on cells was identified by flow cytometry. Cells were tested using recombinant single-domain human anti-PD-L1 antibodies (nanoantibodies) conjugated with radioisotopes 68 Ga or 177 Lu. Immunoreactive fraction and cell internalization of the radioconjugates were evaluated in vitro. For in vivo experiments CT26-PD-L1 cells were transplanted into mice, radioimmunoconjugates were injected 9-14 days later, in 1-48 h the tumors were retrieved and subjected to direct radiometry. Intact CT26 cells not expressing the antigen served as a control. Results. CT26-PD-L1 strain of murine tumor cells expressing human membrane PD-L1 was created. When transplanted into intact BALB/c mice or sublethally irradiated F1(DBAxBALB/c) mice, these cells formed tumors. Thus, a significant advantage of the model was the possibility of in vivo testing of human PD-L1-affinity agents using animals under conventional vivarium conditions. When radioimmunoconjugates were administered to tumor bearing mice, radionuclides accumulated in tumors generated from the transplanted CT26-PD-L1 cells, but not CT26 cells. CT26-PD-L1 cells internalized anti-PD-L1 nanobodies in vitro. Due to a high density of target molecules, CT26-PD-L1 cells allowed both to confirm pharmaceuticals' specificity and to quantify the target-binding fraction of conjugates in a single test. Conclusion. The created cells are the first genetically engineered cells designed to evaluate affinity of anti-human PD-L1 therapeutic and diagnostic agents in Russia. Test results confirmed the model suitability for in vitro and in vivo testing of the specificity of pharmaceuticals targeting human PD-L1.

12 March 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
ABAnastasia Belevich
Anastasia Belevich
MYMaria Yarmolinskaya
Maria Yarmolinskaya
ISIlya Smirnov
Ilya Smirnov
ASAnastasia Stolbovaya
Anastasia Stolbovaya
OSOlga Shashkova
Olga Shashkova
Dmitry I SokolovDmitry I Sokolov
Dmitry I Sokolov
Background: Endometriosis is a complex condition that impairs women’s quality of life and reproductive potential. Its diagnosis remains significant challenge for clinicians. The aim of the study was to investigate cancer-like immune evasion mechanisms in endometriosis and to develop a novel diagnostic model using machine learning. Methods: In this study, we measured the levels of soluble forms of the following immune markers in blood serum and peritoneal fluid (PF): sMICA, sMICB, sEng, sCD25, s4-1BB, sB7.2, sCTLA-4, sPD-L1, sPD-1, sTIM-3, sLAG-3, and sGal-9. Results: sMICB levels in PF differed across endometriosis stages and were higher in patients with endometriosis-associated adhesions. sMICA levels in PF were elevated in women with endometriosis-associated infertility. The disease severity was inversely correlated with serum sB7.2 levels and positively correlated with serum sTIM-3 levels. A logistic regression model achieved an accuracy = 0.79, AUC = 0.94, and F1-score = 0.88, whereas XGBoost performed better with accuracy = 0.94, AUC = 0.95, and F1-score = 0.96. The key predictive features in both models were sMICB serum level and patients’ pain score. Conclusions: Our results demonstrate the potential role of sMICA and sMICB shedding in endometriosis and present a novel, minimally invasive diagnostic approach.

1 December 2024 in Nanobiotechnology Reports
Verified
Journal Article
Closed access
PDF file
OSOlga Shashkova
Olga Shashkova
NVN. A. Verlov
N. A. Verlov
KAK. O. Avrov
K. O. Avrov
SSS. V. Soloveva
S. V. Soloveva
LTL. A. Terekhina
L. A. Terekhina
AKA. L. Konevega
A. L. Konevega
Terbium-161 is a radioisotope characterized by β-emission, emission of Auger electrons, conversion electrons, and, to a lesser extent, gamma and X-rays. Tb-161 radioconjugate with the DOTA-PSMA-617 ligand (considered as a promising drug for radiotherapy of prostate cancer) was synthesized on the basis of components produced in Russian Federation. The physicochemical characteristics of 161Tb-DOTA-PSMA-617 were investigated. The ability of the radioconjugate to bind to cell membrane receptor was studied on cell line in vitro and in mice in vivo using a new CT26-PSMA cell model representing genetically modified mouse carcinoma cells expressing human PSMA. The pharmacokinetics and biodistribution of the radioconjugate were investigated. The radiopharmaceutical demonstrated highly specific accumulation in the tumor expressing human PSMA unlike in the control tumor. It was not significantly accumulated in the kidneys and other animals’ organs. The blood half-life time of the radiopharmaceutical was determined as 38.4 min. Thus, according to the main criteria, the synthesized radioconjugate 161Tb-DOTA-PSMA-617 is a promising radiopharmaceutical for the treatment of prostate cancer.

14 December 2023 in Applied Biochemistry and Microbiology
Verified
Journal Article
Closed access
PDF file
OSOlga Shashkova
Olga Shashkova
ISI. V. Smirnov
I. V. Smirnov
APA. A. Pinevich
A. A. Pinevich
KAK. O. Avrov
K. O. Avrov
LTL. A. Terekhina
L. A. Terekhina
MSM. P. Samoilovich
M. P. Samoilovich
One of the most important characteristics of radiolabeled antibodies and their derivatives is the size of the immunoreactive fraction. Measuring this parameter requires a high density of target molecules, which is rarely achievable with tumor cells. The solution to the problem of radioimmunoconjugate testing was the creation of recombinant cells carrying human endoglin (CD105). The recipients of the endoglin gene (ENG) were rat C6 glioma cells, which are characterized by ease of cultivation and high transfection efficiency. The obtained C6-ENG cells carried 1.3 × 106 CD105 molecules on the membrane and were used to determine the immunoreactive fraction of 68Ga and 89Zr radiolabeled anti-CD105 monoclonal antibodies and their Fab-fragments. The creation of stable recombinant cell lines for in vitro testing the specific activity of radiolabeled antibodies and their derivatives seems promising for the development of new radiopharmaceuticals.

Verified
Journal Article
Open access
PDF file
ALAleksandr Lunev
Aleksandr Lunev
KPKristina Petrosova
Kristina Petrosova
MRMarat Rakhimov
Marat Rakhimov
AUAnastasia Uspenskaya
Anastasia Uspenskaya
AMAleksei Machulkin
Aleksei Machulkin
ALAnton A. Larenkov
Anton A. Larenkov
Preclinical models play a critical role in the development of PSMA-targeted radiopharmaceuticals for prostate cancer. However, many existing models have practical limitations, including slow tumor growth, low engraftment rates, and restricted availability, and all human PSMA-positive lines are confined to immunodeficient hosts. We developed and characterized a novel PSMA-expressing transgenic cell line, CT26-PSMA, as a practical tool for preclinical screening of PSMA-targeting agents. The CT26-PSMA cell line was established by stable transfection of the murine colon carcinoma CT26 cell line with human PSMA using the Sleeping Beauty transposon system. PSMA expression was confirmed by RT-qPCR (reverse transcription quantitative polymerase chain reaction), flow cytometry, and radioligand saturation binding on intact cells. Two [68Ga]Ga-labeled radioconjugates—the well-established PSMA-617 and a newly synthesized conjugate (Conjugate-1)—were used to validate the functionality of the model through in vitro binding, uptake and internalization studies, and through ex vivo biodistribution in CT26-PSMA tumor-bearing athymic male nu/nu mice. The CT26-PSMA cell line demonstrated high and stable PSMA expression, with approximately 95% of cells expressing the biomarker and no measurable loss over 16 passages in antibiotic-free medium. Saturation binding gave a receptor density of ∼3.5 × 106 sites per cell, approximately four-fold higher than that of LNCaP cells (∼0.8 × 106), with dissociation constants that were indistinguishable between the two radioconjugates and between the two cell lines (Kd 9.0–11.6 nM). Subcutaneous tumors reached ~300 mm3 within 8–10 days of inoculation, with a take rate of 10/10 versus 1/10 for LNCaP (Fisher’s exact test, p = 1.2 × 10−4). Both radiotracers showed saturable, 2-PMPA-blockable binding and uptake in CT26-PSMA cells, confirming the functional activity of the recombinant receptor. Biodistribution studies revealed accumulation of both conjugates in CT26-PSMA tumors, with generally comparable tumor-to-background profiles. The CT26-PSMA cell line represents a robust, rapid, and reproducible platform for preclinical evaluation of PSMA-targeting radiopharmaceuticals, and its murine BALB/c origin permits engraftment in immunocompetent or minimally immunosuppressed hosts, whereas existing human PSMA-positive lines do not. It is intended as a screening platform rather than as a model of prostate cancer biology. The validation data obtained with [68Ga]Ga-labelled conjugates confirm the suitability of this cell line for future studies of PSMA-directed compounds.